Vasant Jadhav

High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination academic.oup.com/nar/article/do…

@JMaraganore That background suits you well :)

Found my seat at the airport! 🤣

26 years after arriving in US. The baggage tag is still there showing multiple halts of the long journey. It has been a great ride since arriving in Beautiful Boulder to now in Boston Strong.

Great insights from Bruce and Atlas team.

Developers use operating systems like iOS or Android to quickly and easily create new apps. We use our #RNAiTherapeutics platform similarly to quickly develop investigational medicines. A new @NaturePortfolio article (sponsored content; for US audiences only) explains how. #RNAi

@JMaraganore @Alnylam John- Such a joy chatting with you…always has been.

One of the greatest things about Boston…. Running into friends and former colleagues like Vasant Jadhav, @Alnylam CTO!!!

@JMaraganore @Alnylam Great summary, John. The vutri dose of 100 mg for ONE YEAR (25 mg x q3M) is close to many small molecule drugs taken EVERY DAY. In some cases, it is lot LESS.

This was a big week for my @Alnylam friends and colleagues, and it was because of a molecule once called ALN-TTRsc02, now vutrisiran or AMVUTTRA. Some of you may be curious to learn its story. 1/

Bros of Alnylam R&D- Pushkal, Kevin, Akshay

@Alnylam This Moment invokes the comparisons like EYLEA for REGN and KALYDECO for VERTEX

We are pleased to share positive topline results from our HELIOS-B Phase 3 study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis w/ cardiomyopathy. Read the press release: bit.ly/3VwvRtY #RNAiTherapeutics #siRNA

Evaluating the oral delivery of GalNAc-conjugated siRNAs in rodents and non-human primates academic.oup.com/nar/article/do…

@NatureBiotech Towards that expansion, emerging profile of Zilebesiran looks encouraging. x.com/Alnylam/status…

With six approved drugs, siRNA is now an established therapeutic modality poised for expansion go.nature.com/49tcrf8 rdcu.be/dAsb2

@JMaraganore Few familiar faces…ALL the Best!

The start of something very very exciting! More soon!

@JMaraganore Welcome CRISPR to the club of advanced medicines based on nucleic acids. Congratulations to all who made this milestone possible from discovery to approval in record time!

Terrific milestone for a new frontier of medicine! I’ve seen it before and I like what I see! Congrats to all the gene editing innovators!

Akshay reflecting on Alnylam resilience in fireside chat with Jason Rhodes at the Atlas Retreat.

@LifeSciVC Bruce’s 2023 review was the Treat at the Retreat

Our 30th annual #AtlasRetreat2023 kicked off today… great mix of biotech, pharma, and investment folks… good to see the $XBI ripping as we try to discuss the nuggets of optimism in these challenging markets!

@JMaraganore And getting the drug approval is like winning the superbowl ring as a team. Five from Alny!

Watching football tonight… Reminds me: biotech leaders are like quarterbacks. On the field with their teammates. Call some plays and adjust as needed. Win as team, not as individual. Get hit, dirty, and sometimes sacked. They’re not on sidelines (coach) or in owner’s box

What a fantastic Nature meeting with unique agenda- optional *FREE* CAREER DAY and who’s who of RNA World speakers! conferences.nature.com/ZLONmr?sms=2

Wonderful to see this work published showing human translation of ESC+ design. From concept to clinic. journal-of-hepatology.eu/article/S0168-…

Continues to look impressive! Go Leqvio and GalNAc-siRNA Platform! Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years novartis.com/news/media-rel…